Dana-Farber-Cancer Institute Inc.

Kymab Limited

Bettina Franz

Glenn Dranoff

Kai W Wucherpfennig

F Stephen Hodi

Christopher Harvey

Kenneth F May, Jr

Ian Kirby

Steve Holmes

Jamie Iain Campbell

Anais Legent

Kenneth May

The present disclosure provides, in part, compositions comprising peptides that immunospecifically bind to a defined binding partner, such as MHC class I polypeptide-related sequence A (MICA), or an epitope thereon. In some embodiments, the peptides comprise one or more complementarity determining regions relating to the complementarity regions shown in Table 1. The disclosure also provides methods of treating cancer in a subject using the compositions disclosed herein, and methods of isolating human antibodies from cancer patients following immunotherapy.

Therapeutic peptides

The present disclosure provides, in part, compositions comprising peptides immuno specifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.

The present invention relates to anti-human LIGHT antibodies, new medical uses and methods.

Anti-LIGHT antibodies

The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to MHC class I polypeptide-related sequence A (MICA).

Antibodies that bind to MHC class I polypeptide-related sequence A

The present disclosure provides, in part, compositions comprising an antibody or antibody fragment that immunospecifically binds to MCH class I polypeptide-related sequence A (MICA), or an epitope thereof.

Growing community of inventors

Orem, UT, United States of America

Bettina Franz